Analystreport

NeuBase Therapeutics, Inc. (NASDAQ: NBSE) had its price target lowered by analysts at Chardan Capital from $18.00 to $9.00.

NeuBase Therapeutics, Inc.  (NBSE) 
Last neubase therapeutics, inc. earnings: 3/26 04:05 pm Check Earnings Report